^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Anal Carcinoma
    Drug:carboplatin (Tubulin polymerization promoter) +
    paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Published date:
    09/01/2021
    Excerpt:
    Carboplatin in combination with paclitaxel should be considered a new standard of care in patients with ChT-naive advanced anal cancer [I, B].
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …carboplatin in combination with paclitaxel has been noted as the preferred regimen for first-line treatment of metastatic anal cancer by the NCCN Panel.